Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial. Verberkt, C. A., Everdingen, M. H. J. v. d. B., Schols, J. M. G. A., Hameleers, N., Wouters, E. F. M., & Janssen, D. J. A. JAMA Internal Medicine, August, 2020.
Paper doi abstract bibtex \textlessh3\textgreaterImportance\textless/h3\textgreater\textlessp\textgreaterMorphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.\textless/p\textgreater\textlessh3\textgreaterObjective\textless/h3\textgreater\textlessp\textgreaterTo assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.\textless/p\textgreater\textlessh3\textgreaterInterventions\textless/h3\textgreater\textlessp\textgreaterParticipants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.\textless/p\textgreater\textlessh3\textgreaterDesign, Setting, and Participants\textless/h3\textgreater\textlessp\textgreaterThe Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a randomized, double-blind, and placebo-controlled study of a 4-week intervention. Patients were enrolled between November 1, 2016, and January 24, 2019. Participants were recruited in a pulmonary rehabilitation center and 2 general hospitals after completion of a pulmonary rehabilitation program. Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included. A total of 1380 patients were screened, 916 were ineligible, and 340 declined to participate.\textless/p\textgreater\textlessh3\textgreaterMain Outcomes and Measures\textless/h3\textgreater\textlessp\textgreaterPrimary outcomes were CAT score (higher scores represent worse health status) and arterial partial pressure of carbon dioxide (Paco$_{\textrm{2}}$). Secondary outcome was breathlessness in the previous 24 hours (numeric rating scale). Data were analyzed by intention to treat. Subgroup analyses in participants with mMRC grades 3 to 4 were performed.\textless/p\textgreater\textlessh3\textgreaterResults\textless/h3\textgreater\textlessp\textgreaterA total of 111 of 124 included participants were analyzed (mean [SD] age, 65.4 [8.0] years; 60 men [54%]). Difference in CAT score was 2.18 points lower in the morphine group (95% CI, –4.14 to –0.22 points;P = .03). Difference in Paco$_{\textrm{2}}$was 1.19 mm Hg higher in the morphine group (95% CI, –2.70 to 5.07 mm Hg;P = .55). Breathlessness remained unchanged. Worst breathlessness improved in participants with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95% CI, –2.50 to –0.16 points;P = .03). Five participants of 54 in the morphine group (9%) and 1 participant of 57 in the placebo group (2%) withdrew because of adverse effects. No morphine-related hospital admissions or deaths occurred.\textless/p\textgreater\textlessh3\textgreaterConclusions and Relevance\textless/h3\textgreater\textlessp\textgreaterIn this randomized clinical trial, regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD without affecting Paco$_{\textrm{2}}$or causing serious adverse effects. The worst breathlessness improved in participants with mMRC grades 3 to 4. A larger randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 4 is warranted.\textless/p\textgreater\textlessh3\textgreaterTrial Registration\textless/h3\textgreater\textlessp\textgreaterClinicalTrials.gov Identifier:NCT02429050\textless/p\textgreater
@article{verberkt_effect_2020,
title = {Effect of {Sustained}-{Release} {Morphine} for {Refractory} {Breathlessness} in {Chronic} {Obstructive} {Pulmonary} {Disease} on {Health} {Status}: {A} {Randomized} {Clinical} {Trial}},
shorttitle = {Effect of {Sustained}-{Release} {Morphine} for {Refractory} {Breathlessness} in {Chronic} {Obstructive} {Pulmonary} {Disease} on {Health} {Status}},
url = {https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2769373},
doi = {10.1001/jamainternmed.2020.3134},
abstract = {{\textless}h3{\textgreater}Importance{\textless}/h3{\textgreater}{\textless}p{\textgreater}Morphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Objective{\textless}/h3{\textgreater}{\textless}p{\textgreater}To assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Interventions{\textless}/h3{\textgreater}{\textless}p{\textgreater}Participants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Design, Setting, and Participants{\textless}/h3{\textgreater}{\textless}p{\textgreater}The Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a randomized, double-blind, and placebo-controlled study of a 4-week intervention. Patients were enrolled between November 1, 2016, and January 24, 2019. Participants were recruited in a pulmonary rehabilitation center and 2 general hospitals after completion of a pulmonary rehabilitation program. Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included. A total of 1380 patients were screened, 916 were ineligible, and 340 declined to participate.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Main Outcomes and Measures{\textless}/h3{\textgreater}{\textless}p{\textgreater}Primary outcomes were CAT score (higher scores represent worse health status) and arterial partial pressure of carbon dioxide (Paco$_{\textrm{2}}$). Secondary outcome was breathlessness in the previous 24 hours (numeric rating scale). Data were analyzed by intention to treat. Subgroup analyses in participants with mMRC grades 3 to 4 were performed.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Results{\textless}/h3{\textgreater}{\textless}p{\textgreater}A total of 111 of 124 included participants were analyzed (mean [SD] age, 65.4 [8.0] years; 60 men [54\%]). Difference in CAT score was 2.18 points lower in the morphine group (95\% CI, –4.14 to –0.22 points;\textit{P} = .03). Difference in Paco$_{\textrm{2}}$was 1.19 mm Hg higher in the morphine group (95\% CI, –2.70 to 5.07 mm Hg;\textit{P} = .55). Breathlessness remained unchanged. Worst breathlessness improved in participants with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95\% CI, –2.50 to –0.16 points;\textit{P} = .03). Five participants of 54 in the morphine group (9\%) and 1 participant of 57 in the placebo group (2\%) withdrew because of adverse effects. No morphine-related hospital admissions or deaths occurred.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Conclusions and Relevance{\textless}/h3{\textgreater}{\textless}p{\textgreater}In this randomized clinical trial, regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD without affecting Paco$_{\textrm{2}}$or causing serious adverse effects. The worst breathlessness improved in participants with mMRC grades 3 to 4. A larger randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 4 is warranted.{\textless}/p{\textgreater}{\textless}h3{\textgreater}Trial Registration{\textless}/h3{\textgreater}{\textless}p{\textgreater}ClinicalTrials.gov Identifier:NCT02429050{\textless}/p{\textgreater}},
language = {en},
urldate = {2020-10-02},
journal = {JAMA Internal Medicine},
author = {Verberkt, Cornelia A. and Everdingen, Marieke H. J. van den Beuken-van and Schols, Jos M. G. A. and Hameleers, Niels and Wouters, Emiel F. M. and Janssen, Daisy J. A.},
month = aug,
year = {2020},
}
Downloads: 0
{"_id":"uwbYpHR5aJAy4vwPT","bibbaseid":"verberkt-everdingen-schols-hameleers-wouters-janssen-effectofsustainedreleasemorphineforrefractorybreathlessnessinchronicobstructivepulmonarydiseaseonhealthstatusarandomizedclinicaltrial-2020","author_short":["Verberkt, C. A.","Everdingen, M. H. J. v. d. B.","Schols, J. M. G. A.","Hameleers, N.","Wouters, E. F. M.","Janssen, D. J. A."],"bibdata":{"bibtype":"article","type":"article","title":"Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial","shorttitle":"Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status","url":"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2769373","doi":"10.1001/jamainternmed.2020.3134","abstract":"\\textlessh3\\textgreaterImportance\\textless/h3\\textgreater\\textlessp\\textgreaterMorphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.\\textless/p\\textgreater\\textlessh3\\textgreaterObjective\\textless/h3\\textgreater\\textlessp\\textgreaterTo assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.\\textless/p\\textgreater\\textlessh3\\textgreaterInterventions\\textless/h3\\textgreater\\textlessp\\textgreaterParticipants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.\\textless/p\\textgreater\\textlessh3\\textgreaterDesign, Setting, and Participants\\textless/h3\\textgreater\\textlessp\\textgreaterThe Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a randomized, double-blind, and placebo-controlled study of a 4-week intervention. Patients were enrolled between November 1, 2016, and January 24, 2019. Participants were recruited in a pulmonary rehabilitation center and 2 general hospitals after completion of a pulmonary rehabilitation program. Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included. A total of 1380 patients were screened, 916 were ineligible, and 340 declined to participate.\\textless/p\\textgreater\\textlessh3\\textgreaterMain Outcomes and Measures\\textless/h3\\textgreater\\textlessp\\textgreaterPrimary outcomes were CAT score (higher scores represent worse health status) and arterial partial pressure of carbon dioxide (Paco$_{\\textrm{2}}$). Secondary outcome was breathlessness in the previous 24 hours (numeric rating scale). Data were analyzed by intention to treat. Subgroup analyses in participants with mMRC grades 3 to 4 were performed.\\textless/p\\textgreater\\textlessh3\\textgreaterResults\\textless/h3\\textgreater\\textlessp\\textgreaterA total of 111 of 124 included participants were analyzed (mean [SD] age, 65.4 [8.0] years; 60 men [54%]). Difference in CAT score was 2.18 points lower in the morphine group (95% CI, –4.14 to –0.22 points;<i>P</i> = .03). Difference in Paco$_{\\textrm{2}}$was 1.19 mm Hg higher in the morphine group (95% CI, –2.70 to 5.07 mm Hg;<i>P</i> = .55). Breathlessness remained unchanged. Worst breathlessness improved in participants with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95% CI, –2.50 to –0.16 points;<i>P</i> = .03). Five participants of 54 in the morphine group (9%) and 1 participant of 57 in the placebo group (2%) withdrew because of adverse effects. No morphine-related hospital admissions or deaths occurred.\\textless/p\\textgreater\\textlessh3\\textgreaterConclusions and Relevance\\textless/h3\\textgreater\\textlessp\\textgreaterIn this randomized clinical trial, regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD without affecting Paco$_{\\textrm{2}}$or causing serious adverse effects. The worst breathlessness improved in participants with mMRC grades 3 to 4. A larger randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 4 is warranted.\\textless/p\\textgreater\\textlessh3\\textgreaterTrial Registration\\textless/h3\\textgreater\\textlessp\\textgreaterClinicalTrials.gov Identifier:NCT02429050\\textless/p\\textgreater","language":"en","urldate":"2020-10-02","journal":"JAMA Internal Medicine","author":[{"propositions":[],"lastnames":["Verberkt"],"firstnames":["Cornelia","A."],"suffixes":[]},{"propositions":[],"lastnames":["Everdingen"],"firstnames":["Marieke","H.","J.","van","den","Beuken-van"],"suffixes":[]},{"propositions":[],"lastnames":["Schols"],"firstnames":["Jos","M.","G.","A."],"suffixes":[]},{"propositions":[],"lastnames":["Hameleers"],"firstnames":["Niels"],"suffixes":[]},{"propositions":[],"lastnames":["Wouters"],"firstnames":["Emiel","F.","M."],"suffixes":[]},{"propositions":[],"lastnames":["Janssen"],"firstnames":["Daisy","J.","A."],"suffixes":[]}],"month":"August","year":"2020","bibtex":"@article{verberkt_effect_2020,\n\ttitle = {Effect of {Sustained}-{Release} {Morphine} for {Refractory} {Breathlessness} in {Chronic} {Obstructive} {Pulmonary} {Disease} on {Health} {Status}: {A} {Randomized} {Clinical} {Trial}},\n\tshorttitle = {Effect of {Sustained}-{Release} {Morphine} for {Refractory} {Breathlessness} in {Chronic} {Obstructive} {Pulmonary} {Disease} on {Health} {Status}},\n\turl = {https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2769373},\n\tdoi = {10.1001/jamainternmed.2020.3134},\n\tabstract = {{\\textless}h3{\\textgreater}Importance{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}Morphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Objective{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}To assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes, and breathlessness in patients with COPD.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Interventions{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}Participants were randomly assigned to 10 mg of regular, oral sustained-release morphine or placebo twice daily for 4 weeks, with the possibility to increase to 3 times daily after 1 or 2 weeks.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Design, Setting, and Participants{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}The Morphine for Treatment of Dyspnea in Patients With COPD (MORDYC) study was a randomized, double-blind, and placebo-controlled study of a 4-week intervention. Patients were enrolled between November 1, 2016, and January 24, 2019. Participants were recruited in a pulmonary rehabilitation center and 2 general hospitals after completion of a pulmonary rehabilitation program. Outpatients with COPD and moderate to very severe chronic breathlessness (modified Medical Research Council [mMRC] breathlessness grades 2-4) despite optimal pharmacological and nonpharmacological treatment were included. A total of 1380 patients were screened, 916 were ineligible, and 340 declined to participate.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Main Outcomes and Measures{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}Primary outcomes were CAT score (higher scores represent worse health status) and arterial partial pressure of carbon dioxide (Paco$_{\\textrm{2}}$). Secondary outcome was breathlessness in the previous 24 hours (numeric rating scale). Data were analyzed by intention to treat. Subgroup analyses in participants with mMRC grades 3 to 4 were performed.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Results{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}A total of 111 of 124 included participants were analyzed (mean [SD] age, 65.4 [8.0] years; 60 men [54\\%]). Difference in CAT score was 2.18 points lower in the morphine group (95\\% CI, –4.14 to –0.22 points;\\textit{P} = .03). Difference in Paco$_{\\textrm{2}}$was 1.19 mm Hg higher in the morphine group (95\\% CI, –2.70 to 5.07 mm Hg;\\textit{P} = .55). Breathlessness remained unchanged. Worst breathlessness improved in participants with mMRC grades 3 to 4 (1.33 points lower in the morphine group; 95\\% CI, –2.50 to –0.16 points;\\textit{P} = .03). Five participants of 54 in the morphine group (9\\%) and 1 participant of 57 in the placebo group (2\\%) withdrew because of adverse effects. No morphine-related hospital admissions or deaths occurred.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Conclusions and Relevance{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}In this randomized clinical trial, regular, low-dose, oral sustained-release morphine for 4 weeks improved disease-specific health status in patients with COPD without affecting Paco$_{\\textrm{2}}$or causing serious adverse effects. The worst breathlessness improved in participants with mMRC grades 3 to 4. A larger randomized clinical trial with longer follow-up in patients with mMRC grades 3 to 4 is warranted.{\\textless}/p{\\textgreater}{\\textless}h3{\\textgreater}Trial Registration{\\textless}/h3{\\textgreater}{\\textless}p{\\textgreater}ClinicalTrials.gov Identifier:NCT02429050{\\textless}/p{\\textgreater}},\n\tlanguage = {en},\n\turldate = {2020-10-02},\n\tjournal = {JAMA Internal Medicine},\n\tauthor = {Verberkt, Cornelia A. and Everdingen, Marieke H. J. van den Beuken-van and Schols, Jos M. G. A. and Hameleers, Niels and Wouters, Emiel F. M. and Janssen, Daisy J. A.},\n\tmonth = aug,\n\tyear = {2020},\n}\n\n","author_short":["Verberkt, C. A.","Everdingen, M. H. J. v. d. B.","Schols, J. M. G. A.","Hameleers, N.","Wouters, E. F. M.","Janssen, D. J. A."],"key":"verberkt_effect_2020","id":"verberkt_effect_2020","bibbaseid":"verberkt-everdingen-schols-hameleers-wouters-janssen-effectofsustainedreleasemorphineforrefractorybreathlessnessinchronicobstructivepulmonarydiseaseonhealthstatusarandomizedclinicaltrial-2020","role":"author","urls":{"Paper":"https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2769373"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://bibbase.org/zotero/ckelleyt","dataSources":["W5PhLT7vuF6ko8d7J","tTydwtpFKyvDpy8qn"],"keywords":[],"search_terms":["effect","sustained","release","morphine","refractory","breathlessness","chronic","obstructive","pulmonary","disease","health","status","randomized","clinical","trial","verberkt","everdingen","schols","hameleers","wouters","janssen"],"title":"Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial","year":2020}